Atossa Therapeutics, a clinical-stage biopharmaceutical company, centers its pipeline on the oral selective estrogen receptor modulator/degrader (Z)-endoxifen, currently in Phase 2 trials targeting breast cancer and select rare diseases. Growth has been hampered by sustained operating losses driven by increased research and development investment. With patent protection secured until 2038 and orphan drug designations attained, Atossa’s prospects hinge on clinical advancement and capital availability. The company ended 2025 with $41 million cash, but continued negative cash flows underscore the need for additional funding to support operations beyond the next year.